Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22
Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.
Share
Why It Matters
An analyst still thinks Integra is a good pick compared to the market. But they lowered their price guess from $25 to $22 per share.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.